By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Spero Acquires Novel Gyrase Inhibitors From Vertex (VRTX) 5/25/2016 6:39:37 AM
Vertex (VRTX) CEO Took a 23% Pay Cut in 2015 as Firm Overhauls Compensation Policies 4/29/2016 8:50:21 AM
Vertex (VRTX) Reports First Quarter 2016 Financial Results 4/28/2016 10:20:06 AM
Enterome In-Licenses Novel Compounds From Vertex (VRTX) To Treat Microbiome-Related Inflammatory Bowel Diseases 4/18/2016 10:14:32 AM
Vertex (VRTX) To Announce First Quarter 2016 Financial Results On April 27 4/15/2016 9:16:19 AM
Vertex (VRTX) To Present At The Barclays Healthcare Conference On March 15 3/11/2016 10:01:37 AM
Hovione And Vertex (VRTX) Partner In Continuous Manufacturing 3/10/2016 7:26:23 AM
Vertex (VRTX) Receives Australian Approval For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation 3/9/2016 11:06:49 AM
Vertex (VRTX) Awards $1 Million In Grants To 18 Non-Profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis 2/24/2016 11:22:11 AM
Three Dinged Biopharmas that Could Make a Fierce Comeback 2/16/2016 7:48:51 AM